Based on your previous selection, you have been forwarded to the website for International.

XL CDKN2A

Deletion Probe

Order Number
D-5053-100-OG
Package Size
100 µl (10 Tests)
Labels
  
Chromosome
9
Regulatory Status
IVDD

IVDR Certification

This probe is IVDR-certified in compliance with the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR).

MetaSystems Probes has already certified a large part of its portfolio, according to IVDR. For organizational reasons, we currently provide only the IVDD product.

Please use the switch to change to the IVDR product.

IVDDIVDRDiscover all IVDR-certified products

Product Description

XL CDKN2A

XL CDKN2A consists of an orange-labeled probe hybridizing to the CDKN2A (p16)/CDKN2B (p15) gene region at 9p21 and a green-labeled probe hybridizing to the centromere of chromosome 9.

Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.

Need assistance or a quote?

Clinical Details

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer type. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive and quickly progressing type of ALL affecting T-lymphocytes. Inactivation of the tumor suppressor genes CDKN2A/2B, located at chromosomal region 9p21, is a significant event in the development of T-ALL and other cancer types. Principally, loss of function might happen by deletion, methylation of promotor regions or mutations, whereas deletion of chromosomal region 9p21 seems to be the predominant mechanism. CDKN2A/2B deletions can be detected in about 60% of pediatric and about 50% of adult T-ALL cases. Most deletions are within the resolution of the FISH technique. Genetic alterations of the 9p21 locus result in loss of regulation of the cell cycle which is critical to cancer development.

Clinical Applications

  • Acute Lymphoblastic Leukemia (ALL)
Need assistance or a quote?

Images

XL CDKN2A

XL CDKN2A hybridized to bone marrow cells. Two normal cells and several cells with two green signals are shown indicating a homozygous deletion of the CDKN2A.

Need assistance or a quote?

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange (2O) signals.

Expected Pattern 2

Aberrant Cell (typical results):
Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.

Expected Pattern 3

Aberrant Cell (typical results):
Two green (2G) and no orange
(no O) signal resulting from homozygous deletion of the locus covered by the orange probe.

Need assistance or a quote?

Literature

  • Novara et al (2009) Human Genet 126:511-520
  • Sulong et al (2009) Blood 113:100-107
  • Girardi et al (2017) Blood 129:1113-1123

Downloads

News

MetaSystems DM2019 Largest in History

About 100 guests from 36 countries met on the XVIII. MetaSystems Distributor Meeting (DM) in November to exchange experiences and to get to know new trends and developments at MetaSystems.

MetaSystems DM2019 Largest in History

Second MetaSystems User Day in Altlussheim, Germany

Neon, the outstanding MetaSystems case and image management system, offers many tools and helpful gadgets to streamline routine workflows, for example in cytogenetics labs. The second MetaSystems User Day, addressed to MetaSystems clients from Germany, Austria, and Switzerland, provided in different workshops knowledge helping to unleash the full power of the system.

Second MetaSystems User Day in Altlussheim, Germany